Dyne Therapeutics (NASDAQ:DYN) Now Covered by Analysts at Oppenheimer

Oppenheimer initiated coverage on shares of Dyne Therapeutics (NASDAQ:DYN - Free Report) in a report issued on Monday morning, Marketbeat reports. The brokerage issued an outperform rating and a $34.00 price objective on the stock.

Several other research firms also recently issued reports on DYN. Evercore ISI began coverage on Dyne Therapeutics in a research report on Thursday, May 29th. They issued an "outperform" rating and a $46.00 target price on the stock. JPMorgan Chase & Co. cut their target price on Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating on the stock in a research report on Friday, March 21st. Scotiabank began coverage on Dyne Therapeutics in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 target price on the stock. BMO Capital Markets began coverage on Dyne Therapeutics in a research report on Wednesday, March 12th. They issued an "outperform" rating and a $50.00 target price on the stock. Finally, Chardan Capital reissued a "buy" rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Dyne Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $45.54.

Dyne Therapeutics Price Performance

NASDAQ DYN traded up $0.57 on Monday, hitting $13.27. The stock had a trading volume of 1,752,492 shares, compared to its average volume of 1,635,159. The business's fifty day moving average price is $10.33 and its 200 day moving average price is $16.00. Dyne Therapeutics has a 52-week low of $6.36 and a 52-week high of $47.45. The stock has a market cap of $1.51 billion, a price-to-earnings ratio of -3.73 and a beta of 1.19.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.17). As a group, sell-side analysts anticipate that Dyne Therapeutics will post -3.44 EPS for the current year.

Institutional Investors Weigh In On Dyne Therapeutics

Hedge funds have recently modified their holdings of the company. GF Fund Management CO. LTD. purchased a new stake in shares of Dyne Therapeutics during the 4th quarter worth about $50,000. GAMMA Investing LLC boosted its stake in shares of Dyne Therapeutics by 837.5% during the 1st quarter. GAMMA Investing LLC now owns 2,625 shares of the company's stock worth $251,000 after acquiring an additional 2,345 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in shares of Dyne Therapeutics by 378.6% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company's stock worth $32,000 after acquiring an additional 2,446 shares in the last quarter. KBC Group NV boosted its stake in shares of Dyne Therapeutics by 45.3% during the 4th quarter. KBC Group NV now owns 3,135 shares of the company's stock worth $74,000 after acquiring an additional 978 shares in the last quarter. Finally, Quarry LP purchased a new stake in shares of Dyne Therapeutics during the 1st quarter worth about $47,000. 96.68% of the stock is owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.